A bipartisan group of senators is working to lower the cost of insulin for millions of Americans. The proposed legislation would cap the monthly cost of the life-saving drug at $35 for individuals with private insurance plans.

The INSULIN Act: Key Provisions

The bill, introduced last week by Senators Jeanne Shaheen (D-Maine), Raphael Warnock (D-Ga.), Susan Collins (R-Maine), and John Kennedy (R-La.), also includes a pilot program to increase access to affordable insulin for uninsured Americans in ten states. This initiative builds on previous efforts to address insulin affordability.

Previous Efforts and Current Challenges

A similar measure was included in the 2022 Inflation Reduction Act, successfully lowering out-of-pocket costs for Medicare beneficiaries. However, many patients remain affected by high prices. Approximately 57% of Americans with private insurance have self-insured plans that are not subject to state cost-cap regulations, according to Matthew Fiedler of the Brookings Institution.

Industry Response and Patient Impact

Pharmaceutical companies have expressed support for affordability initiatives. Oliver Bogillot, head of general medicines for North America at Sanofi, stated, “no one should struggle to afford their insulin” and highlighted the company’s savings program. Novo Nordisk’s spokesperson, Flavia Brakling, noted the company has not raised list prices for its insulin products for 2026.

However, concerns remain about access. Dr. Leslie Eiland, an endocrinologist at the University of Nebraska Medical Center, emphasized that current programs “puts the onus on the patient” to navigate complex cost-saving options. Chanse Jones, a spokesperson for PhRMA, pointed to pharmacy benefit managers and insurers as potential barriers to affordability.

Personal Stories Highlight the Need

Breana Glover, a 23-year-old restaurant server in Houston, relocated from California to manage her diabetes-related healthcare expenses. She carefully limits her carbohydrate intake to stretch her insulin supply, as she pays a $50 co-pay for each vial. Glover believes a $35 cap would significantly improve her financial situation and access to essential resources.

Looking Ahead: Bipartisan Support and Potential Hurdles

Advocates, like Manny Hernandez, CEO of The Diabetes Link, are encouraged by recent engagement with Republican lawmakers but remain cautious. Past attempts to pass similar legislation have stalled due to competing priorities and procedural objections. A $35 insulin cap previously passed by the House in 2022 failed to advance in the Senate.

Approximately 8.1 million Americans use insulin, according to the U.S. Centers for Disease Control and Prevention, with over 2 million relying on it for survival. Despite the challenges, advocates maintain hope for a bipartisan victory on healthcare affordability.